Get the Stockscreener App
3.99
3.16%
-0.13
After Hours:
3.99
Relay Therapeutics Inc stock is traded at $3.99, with a volume of 1.29M.
It is down -3.16% in the last 24 hours and up +19.10% over the past month.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
See More
Previous Close:
$4.12
Open:
$4.08
24h Volume:
1.29M
Relative Volume:
0.70
Market Cap:
$687.92M
Revenue:
$25.55M
Net Income/Loss:
$-341.97M
P/E Ratio:
-1.425
EPS:
-2.8
Net Cash Flow:
$-304.44M
1W Performance:
-3.16%
1M Performance:
+19.10%
6M Performance:
+9.02%
1Y Performance:
-47.64%
1-Day Range:
$3.97
$4.087
1-Week Range:
$3.865
$4.202
52-Week Range:
$1.775
$8.315
Relay Therapeutics Inc Stock (RLAY) Company Profile
Name
Relay Therapeutics Inc
Sector
Industry
Phone
617-370-8837
Address
60 HAMPSHIRE STREET, CAMBRIDGE
Compare RLAY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RLAY
Relay Therapeutics Inc
|
3.99 | 699.99M | 25.55M | -341.97M | -304.44M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-25 | Resumed | Guggenheim | Buy |
| Apr-17-25 | Initiated | Wells Fargo | Equal Weight |
| Sep-10-24 | Resumed | Goldman | Buy |
| Sep-10-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-10-24 | Downgrade | Oppenheimer | Outperform → Perform |
| May-10-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Apr-20-23 | Upgrade | Jefferies | Underperform → Hold |
| Apr-19-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Apr-13-23 | Initiated | Raymond James | Outperform |
| Feb-03-23 | Initiated | Oppenheimer | Outperform |
| Sep-30-22 | Initiated | Barclays | Equal Weight |
| Sep-02-22 | Initiated | Stifel | Buy |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| Feb-01-22 | Initiated | Berenberg | Buy |
| Jul-21-21 | Initiated | BofA Securities | Buy |
| Dec-15-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-08-20 | Initiated | JMP Securities | Mkt Outperform |
| Nov-05-20 | Initiated | H.C. Wainwright | Buy |
| Aug-10-20 | Initiated | Cowen | Outperform |
| Aug-10-20 | Initiated | Goldman | Buy |
| Aug-10-20 | Initiated | Guggenheim | Buy |
| Aug-10-20 | Initiated | JP Morgan | Neutral |
View All
Relay Therapeutics Inc Stock (RLAY) Latest News
Invesco Ltd. Grows Stake in Relay Therapeutics, Inc. $RLAY - MarketBeat
Trexquant Investment LP Has $850,000 Stock Position in Relay Therapeutics, Inc. $RLAY - MarketBeat
OMERS ADMINISTRATION Corp Makes New Investment in Relay Therapeutics, Inc. $RLAY - MarketBeat
Parkman Healthcare Partners LLC Has $493,000 Position in Relay Therapeutics, Inc. $RLAY - MarketBeat
Relay Therapeutics’ Promising Phase 2 Study on RLY-2608: A Potential Game-Changer in Targeted Therapy - MSN
Relay Therapeutics, Inc. $RLAY Shares Sold by Walleye Capital LLC - MarketBeat
Relay Therapeutics (NASDAQ:RLAY) Now Covered by Guggenheim - MarketBeat
Fibonacci Retracement Aligns with Support in Relay Therapeutics Inc.July 2025 Trade Ideas & Real-Time Price Movement Reports - beatles.ru
Relay Therapeutics (NASDAQ:RLAY) Trading Up 7.6%Should You Buy? - MarketBeat
Guggenheim Gives Buy Rating to Relay Therapeutics (RLAY) - Yahoo Finance
Nuveen LLC Invests $839,000 in Relay Therapeutics, Inc. $RLAY - MarketBeat
Will a bounce in Relay Therapeutics Inc. offer an exitMarket Volume Summary & Short-Term Trading Opportunity Alerts - Newser
What’s the profit margin of Relay Therapeutics Inc.July 2025 Macro Moves & Risk Controlled Swing Alerts - خودرو بانک
Is Relay Therapeutics Inc. a defensive stockEarnings Growth Summary & Long-Term Capital Growth Strategies - خودرو بانک
Why Relay Therapeutics Stock Rocketed Nearly 15% Higher This Week - sharewise.com
Relay Therapeutics (RLAY) Stock Rises on Bullish Analyst Note - GuruFocus
Can Relay Therapeutics Inc. expand its profit margins2025 Winners & Losers & Weekly Top Performers Watchlists - خودرو بانک
Tools to assess Relay Therapeutics Inc.’s risk profileEarnings Performance Report & Reliable Breakout Forecasts - Newser
Pattern recognition hints at Relay Therapeutics Inc. upside2025 Key Highlights & Reliable Price Breakout Signals - Newser
What MACD signals say about Relay Therapeutics Inc.Weekly Profit Analysis & Breakout Confirmation Alerts - Newser
Real time breakdown of Relay Therapeutics Inc. stock performance2025 Volume Leaders & Verified Momentum Stock Watchlist - Newser
Predicting Relay Therapeutics Inc. trend using moving averagesMarket Performance Recap & Weekly Stock Performance Updates - Newser
Will Relay Therapeutics Inc. see short term momentumTrade Risk Summary & Long-Term Safe Investment Ideas - Newser
Relay Therapeutics (RLAY) Receives a Buy from Guggenheim - The Globe and Mail
Will Relay Therapeutics Inc. stock hit new highs in YEAR2025 Technical Patterns & AI Forecasted Entry and Exit Points - خودرو بانک
Will Relay Therapeutics Inc. continue its uptrendGlobal Markets & Technical Buy Zone Confirmations - Newser
News impact scoring models applied to Relay Therapeutics Inc.Market Growth Report & Detailed Earnings Play Alerts - Newser
Is Relay Therapeutics Inc. a momentum stock2025 Buyback Activity & AI Powered Market Entry Ideas - خودرو بانک
Guggenheim initiates Relay Therapeutics stock with Buy rating, cites strong oncology pipeline - Investing.com Canada
Momentum divergence signals in Relay Therapeutics Inc. chartWeekly Stock Recap & Consistent Growth Equity Picks - Newser
How moving averages guide Relay Therapeutics Inc. tradingWeekly Gains Summary & Risk Adjusted Buy/Sell Alerts - Newser
What does recent volatility data suggest for Relay Therapeutics Inc.2025 Market Overview & Precise Swing Trade Entry Alerts - Newser
Can Relay Therapeutics Inc. hit a new high this monthDip Buying & Risk Controlled Stock Alerts - Newser
Relay Therapeutics Inc. stock daily chart insightsGap Up & Safe Entry Trade Signal Reports - Newser
What candlestick patterns are forming on Relay Therapeutics Inc.CPI Data & Weekly Breakout Watchlists - Newser
Published on: 2025-09-03 06:45:04 - Newser
Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary - GlobeNewswire Inc.
Is Relay Therapeutics Inc. still worth holding after the dip2025 Stock Rankings & Free AI Powered Buy and Sell Recommendations - Newser
Heatmap analysis for Relay Therapeutics Inc. and competitorsJuly 2025 Trade Ideas & Daily Risk Controlled Trade Plans - Newser
Relay Therapeutics Inc Stock (RLAY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):